盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察

Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer

目的:观察盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效及安全性。方法:回顾分析埃克替尼治疗30例晚期非小细胞肺癌的临床效果,采用口服治疗,125 mg/次,3次/d,评价其近期疗效、无病进展生存期及不良反应。结果:30例患者在接受埃克替尼1个月治疗后,完全缓解(CR)0例,部分缓解(PR)10例,疾病稳定(SD)14例,疾病进展(PD)6例,客观有效率(ORR)为33.3%,疾病控制率(DCR)为80%。在各临床因素中,ECOG评分及是否伴有脑转移与近期疗效具有相关性(P<0.05)。截至随访结束,24例(80%)出现无进展生存期(PFS)终点事件,全组中位PFS为8.0个月。患者的PFS主要与患者年龄、吸烟与否、ECOG评分以及是否伴有其他部位的转移有关(P<0.05)。全组不良反应发生率为43.3%,主要为皮疹5例(16.7%),皮肤瘙痒2例(6.7%),腹泻1例(3.3%),胃部不适1例(3.3%),肝功能轻度损害6例(20.0%)。结论:盐酸埃克替尼治疗晚期非小细胞肺癌疗效肯定,耐受性好。

Objective： To observe the clinical effect and toxicity of icotinib in 30 patients with advanced non-small cell lung cancer （NSCLC）. Methods： Thirty patients with advanced NSCLC were retrospectively analyzed. Icotinib （125 rag,three times a day） was orally taken by patients, to evaluate the short-term response, progression free survival （PFS） and toxicity. Results. Among the 30 patients, no cases experienced complete response（CR）, 10 cases experienced partial response（PR）, 14 cases were with stable diseases（SD）, 6 cases were with progression disease （PD）, and the tumor objective response rate （ORR） and disease control rate （DCR） were 33.3%（10/30） and 80.0%（24/30）, respectively. ECOG and brain metastasis were associated with short-term response. At the end of the follow-up period, twenty-four cases had PD. The median PFS was 8.0 months, significantly correlated with age, smoking history, ECOG, and metastasis （P〈 0.05）. The incidence of side effects was 43.3%, including rash （16.7%） ,itch of skin（6.7%） ,diarrhea（3.3%）, heartburn（3.3%）, and mild impair of liver function（20.0%）. Conclusion： Icotinib hydroehloride is effective with high drug tolerance for advanced NSCLC.